Efficacy and safety of methotrexate in alopecia areata

Anais Brasileiros de Dermatologia

Volumn 89, Issue 5, 2014, Pages 729-734

  Hammerschmidt, Mariana ^a   Brenner, Fabiane Mulinari ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Alopecia areata; Efficacy; Methotrexate

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ADOLESCENT; ADULT; AGE; AGED; ALOPECIA AREATA; DRUG COMBINATION; EVALUATION STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGE FACTORS; AGED; ALOPECIA AREATA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906904704     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/abd1806-4841.20142869     Document Type: Article

References (26)

1. Rivitti E. Alopecia areata: a revision and update. An Bras Dermatol. 2005;80:57-68.
2. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update -Part I. Clinical picture, histopatology and pathogenesis. J Am Acad Dermatol. 2010;62:177-88.
3. Sbd.org.br [Internet]. Sociedade Brasileira de Dermatologia. Censo Dermatológico da SBD. [acesso 1 Dez 2011]. Disponível em: http://www.sbd.org.br/down/censo_dermatologico2006.pdf.
4. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: A long term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55:438-41.
5. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest. 2007;117:2019-27.
6. Gregoriou S, Papafragkaki D, Kontochristopoulos G, Rallis E, Kalogeromitros D, Rigopoulos D. Cytokines and Other Mediators in Alopecia Areata. Mediators Inflamm. 2010;2010:928030.
7. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update, Part II. Treatment. J Am Acad Dermatol. 2010;62:191-202.
8. Joly P. The use of methotrexate alone or in combination with low doses of oral cor-ticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol. 2006;55:632-6.
9. Chartaux E, Joly P. Long-term follow-up of the efficacy of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia area-ta totalis or universalis. Ann Dermatol Venereol. 2010;137:507-13.
10. Droitcourt C, Milpied B, Ezzedine K, Hubiche T, Belin E, Akpadjan F, et al. Interest of High-Dose Pulse Corticosteroid Therapy Combined with Methotrexate for Severe Alopecia Areata: A Retrospective Case Series. Dermatology. 2012;224:369-73.
11. Royer M, Bodemer C, Vabres P, Pajot C, Barbarot S, Paul C, et al. Efficacy and tole-rability of methotrexate in severe childhood AA. Br J Dermatol. 2011;165:407-10.
12. Neves C, Jorge R, Barcelos A. A Teia de Toxicidade do Metotrexato. Acta Reumatol Port. 2009; 34:11-34.
13. Bressan AL, Silva RS, Fontenelle E, Gripp AC. Immunosuppressive agents in Dermatology. An Bras Dermatol. 2010;85:9-22.
14. Conde MB, Melo FAF, Marques AMC, Cardoso NC, Pinheiro VGF, Dalcin PTR, et al. III Brazilian Thoracic Association Guidelines on Tuberculosis. J Bras Pneumol. 2009;35:1018-48.
15. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-asso-ciated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol. 2009;160:622-8.
16. Berends MA, Snoek J, de Jong EM, van de Kerkhof PC, van Oijen MG, van Krieken JH, et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther. 2006;24:805-11.
17. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol. 2001;45:649-61
18. Martins G.A, Arruda L. Systemic treatment of psoriasis - Part I: methotrexate and acitretin. An Bras Dermatol. 2004;79:263-78.
19. Aithal G P, Haugk B, Das S, Card T, Burt AD, Record CO. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther. 2004;19:391-9.
20. Carneiro SC, Cássia F F, Lamy F, Chagas VL, Ramos-e-Silva M. Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages. J Eur Acad Dermatol Venereol. 2008;22:25-9.
21. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998;38:478-85.
22. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol. 2001;45:649-61.
23. Thomas JA, Aithal GP. Monitoring Liver Function during Methotrexate Therapy for Psoriasis. Are Routine Biopsies Really Necessary? Am J Clin Dermatol. 2005;6:357-63.
24. Montaudié H, Sbidian E, Paul C, Maza A, Gallini A, Aractingi S, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol. 2011;25:12-8.
25. Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol. 2011;25:758-64.
26. Laharie D, Seneschal J, Schaeverbeke T, Doutre MS, Longy-Boursier M, Pellegrin JL, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: A case-control study. J Hepatol. 2010;53:1035-40.